成人乙型肝炎疫苗接种专家建议

中华预防医学会促进消除病毒性肝炎工作委员会; 中华预防医学会感染性疾病防控分会

doi:10.12449/JCH240808

成人乙型肝炎疫苗接种专家建议

DOI: 10.12449/JCH240808

利益冲突声明：所有作者均声明不存在利益冲突。

计量
- 文章访问数: 208
- HTML全文浏览量: 276
- PDF下载量: 119
- 被引次数: 0
出版历程
- 收稿日期: 2024-07-22
- 录用日期: 2024-08-03
- 出版日期: 2024-08-25

Expert recommendations on hepatitis B vaccination in adults

Working Committee of Promoting the Elimination of Viral Hepatitis of Chinese Preventive Medicine Association,
Society of Prevention and Control of Infectious Diseases of Chinese Preventive Medicine Association

摘要

摘要: 为了实现2030年消除病毒性肝炎公共卫生危害的目标，发挥乙型肝炎疫苗接种降低乙型肝炎病毒新发感染的作用，中华预防医学会组织专家制定了《成人乙型肝炎疫苗接种专家建议》。本建议旨在科学地指导成人乙型肝炎疫苗接种，提升人群免疫屏障、降低乙型肝炎病毒感染率和乙型肝炎发病率。
- 乙型肝炎 /
- 乙型肝炎疫苗 /
- 接种 /
- 建议
Abstract: In order to achieve the target of eliminating viral hepatitis as a public health threat by 2030 and to prioritize the role of hepatitis B vaccination in reducing new hepatitis B virus infections， the Chinese Preventive Medicine Association commissioned experts to develop the Expert Recommendations on Hepatitis B Vaccination in Adults to scientifically guide adult hepatitis B vaccination， build the herd immunity in population， and reduce the hepatitis B virus infection rate and incidence of hepatitis B.
- Hepatitis B /
- Hepatitis B Vaccine /
- Vaccination /
- Recommendation

HTML全文

表 1 中国可用于成人接种的不同重组乙型肝炎疫苗

Table 1. Various recombinant hepatitis B vaccines for adults in China

疫苗类型	生产商	使用对象	接种剂量
酿酒酵母	深圳康泰生物制品股份有限公司	≥16岁人群	20 μg/1.0 mL、60 μg/1.0 mL
	北京天坛生物制品股份有限公司	≥16岁人群	20 μg/1.0 mL
	葛兰素史克生物有限公司	成人和15岁以上青少年	20 μg/1.0 mL
汉逊酵母	艾美诚信生物制药有限公司	≥16岁人群	10 μg/0.5 mL、20 μg/0.5 mL
CHO细胞	华北制药金坦生物技术股份有限公司	乙型肝炎易感者	10 μg/0.5 mL、20 μg/1.0 mL

下载: 导出CSV

参考文献(47)

[1]	PREBOTH M. PHS guidelines for management of occupational exposure to HBV, HCV and HIV: Management of occupational blood exposures[J]. Am Fam Physician, 2001, 64( 12): 2012- 2014.
[2]	SCHILLIE S, VELLOZZI C, REINGOLD A, et al. Prevention of hepatitis B virus infection in the United States: Recommendations of the advisory committee on immunization practices[J]. MMWR Recomm Rep, 2018, 67( 1): 1- 31. DOI: 10.15585/mmwr.rr6701a1.
[3]	PLOTKIN SA, ORENSTEIN WA, OFFIT PA. Vaccines[M]. 6th ed. LUO FJ, YANG XM, WANG JZ, et al. Trans. Beijing: People’s Medical Pubishing House Co., LTD, 2016. PLOTKIN SA, ORENSTEIN WA, OFFIT PA. Vaccines[M]. 6版. 罗凤基, 杨晓明, 王军志, 等, 译. 北京: 人民卫生出版社, 2016.
[4]	CAO WC. Epidemiology: volume two[M]. 3rd ed. Beijing: People’s Medical Pubishing House Co., LTD, 2015. 曹务春. 流行病学: 第2卷[M]. 3版. 北京: 人民卫生出版社, 2015.
[5]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Chin J Hepatol, 2022, 30( 12): 1309- 1331. DOI: 10.3760/cma.j.cn501113-20221204-00607. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30( 12): 1309- 1331. DOI: 10.3760/cma. j. cn501113-20221204-00607.
[6]	INDOLFI G, EASTERBROOK P, DUSHEIKO G, et al. Hepatitis B virus infection in children and adolescents[J]. Lancet Gastroenterol Hepatol, 2019, 4( 6): 466- 476. DOI: 10.1016/S2468-1253(19)30042-1.
[7]	STINCO M, RUBINO C, TRAPANI S, et al. Treatment of hepatitis B virus infection in children and adolescents[J]. World J Gastroenterol, 2021, 27( 36): 6053- 6063. DOI: 10.3748/wjg.v27.i36.6053.
[8]	HSU YC, HUANG DQ, NGUYEN MH. Global burden of hepatitis B virus: Current status, missed opportunities and a call for action[J]. Nat Rev Gastroenterol Hepatol, 2023, 20( 8): 524- 537. DOI: 10.1038/s41575-023-00760-9.
[9]	CUI FQ, BLACH S, MANZENGO MINGIEDI C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C[J]. Lancet Gastroenterol Hepatol, 2023, 8( 4): 332- 342. DOI: 10.1016/S2468-1253(22)00386-7.
[10]	World Health Organization. Global hepatitis report 2024:action for access in low- and middle-income countries[EB/OL].( 2024-04-09)[ 2024-04-29]. https://www.who.int/publications/i/item/9789240091672. https://www.who.int/publications/i/item/9789240091672
[11]	Collaborators GBD. Global, regional,and national burden of hepatitis B, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 796- 829. DOI: 10.1016/S2468-1253(22)00124-8.
[12]	CAO GY, LIU J, LIU M. Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: Findings from the Global Burden of Disease Study[J]. Chin Med J, 2022, 135( 17): 2049- 2055. DOI: 10.1097/cm9.0000000000002331.
[13]	LIANG XF, BI SL, YANG WZ, et al. Epidemiological serosurvey of hepatitis B in China--Declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2009, 27( 47): 6550- 6557. DOI: 10.1016/j.vaccine.2009.08.048.
[14]	World Health Oganization. Global health sector strategies on, respectively,HIV,viral hepatitis and sexually transmit⁃ted infections for the period 2022- 2030[EB/OL].( 2023-06-18)[ 2024-04-29]. https://cdn. who. int/media/docs/ default-source/hq-hiv-hepatitis-and-stis-library/full-finalwho-ghss-hiv-vh-sti_1-june2022.pdf?sfvrsn=7c074b36_9. https://cdn. who. int/media/docs/ default-source/hq-hiv-hepatitis-and-stis-library/full-finalwho-ghss-hiv-vh-sti_1-june2022.pdf?sfvrsn=7c074b36_9
[15]	CUI FQ, ZHANG GM, SUN XJ. Analysis on susceptibility of hepatitis B virus infection among population aged between 15 and 59 in China[J]. Jiangsu J Prev Med, 2013, 24( 4): 1- 3. DOI: 10.3969/j.issn.1006-9070.2013.04.001. 崔富强, 张国民, 孙校金. 中国15～59岁人群乙型肝炎病毒感染易感性分析[J]. 江苏预防医学, 2013, 24( 4): 1- 3. DOI: 10.3969/j.issn.1006-9070.2013.04.001.
[16]	ZHENG H, WANG FZ, ZHANG GM, et al. The epidemiological characteristics of HBV susceptibility in 1-29 years old young people in China in 2006 and 2014: Based on the national sero-survey data analysis[J]. Chin J Prev Med, 2017, 51( 7): 581- 586. DOI: 10.3760/cma.j.issn.0253-9624.2017.07.002. 郑徽, 王富珍, 张国民, 等. 2006和2014年中国1～29岁乙型肝炎病毒易感人群的流行病学特征分析[J]. 中华预防医学杂志, 2017, 51( 7): 581- 586. DOI: 10.3760/cma.j.issn.0253-9624.2017.07.002.
[17]	WENG MK, DOSHANI M, KHAN MA, et al. Universal hepatitis B vaccination in adults aged 19-59 years:updated recommendations of the advisory committee on immunization practices-United States,2022[J]. MMWR Morb Mortal Wkly Rep, 2022, 71( 13): 477- 483. DOI: 10.15585/mmwr.mm7113a1.
[18]	Chinese Center for Disease Control and Prevention. Annual report on surveillance of infections diseases in China 2022[Z]. 2023-10. 中国疾病预防控制中心. 2022年中国传染病监测报告[Z]. 2023-10.
[19]	World Health Organization. Immunization coverage[EB/OL].( 2023-06-18)[ 2024-04-29]. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage
[20]	MA TL, PAN LL, GAO Z, et al. Influencing factors of coverage rate of hepatitis B vaccine among adults in Hebei Province[J]. Chin Prev Med, 2019, 20( 4): 303- 307. DOI: 10.16506/j.1009-6639.2019.04.014. 马田莉, 潘璐璐, 高招, 等. 河北省成年人乙肝疫苗接种率影响因素研究[J]. 中国预防医学杂志, 2019, 20( 4): 303- 307. DOI: 10.16506/j.1009-6639.2019.04.014.
[21]	LIU DX, ZHU MM. Coverage and influencing factors of vaccination of hepatitis B vaccine among rural residents in Ningbo[J]. Chin J Rural Med Pharm, 2022, 29( 4): 54- 55, 43. DOI: 10.19542/j.cnki.1006-5180.006007. 刘都祥, 朱苗苗. 宁波市2020—2021年成人乙肝疫苗接种现状及其影响因素调查分析[J]. 中国乡村医药, 2022, 29( 4): 54- 55, 43. DOI: 10.19542/j.cnki.1006-5180.006007.
[22]	HSIANG JC, GANE EJ, BAI WW, et al. Type 2 diabetes: a risk factor for liver mortality and complications in hepatitis B cirrhosis patients[J]. J Gastroenterol Hepatol, 2015, 30( 3): 591- 599. DOI: 10.1111/jgh.12790.
[23]	ZHANG XY, WANG YQ, ZHOU YK. Safety of hepatitis B vaccine of children in China:a meta-analysis[J]. Modern Prevent Med, 2015, 42( 9): 1611- 1617. 张雪妍, 王跃锜, 周永康. 国内儿童预防接种乙肝疫苗安全性Meta分析[J]. 现代预防医学, 2015, 42( 9): 1611- 1617.
[24]	GILBERT CL, KLOPFER SO, MARTIN JC, et al. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years[J]. Hum Vaccin, 2011, 7( 12): 1336- 1342. DOI: 10.41601/hv.7.12.18333.
[25]	WAN YM. Comparison of immunogenicity of different hepatitis B vaccine immunization strategies and investigation of vaccination willingness among adults[D]. Beijing: Chinese Center for Disease Control and Prevention, 2021. DOI: 10.27511/d.cnki.gzyyy.2020.000092. 万咏梅. 成人不同乙型肝炎疫苗免疫策略的免疫原性比较和接种意愿调查[D]. 北京: 中国疾病预防控制中心, 2021. DOI: 10.27511/d.cnki.gzyyy.2020.000092.
[26]	ROMANO’L, ZANETTI AR. Hepatitis B vaccination: A historical overview with a focus on the Italian achievements[J]. Viruses, 2022, 14( 7): 1515. DOI: 10.3390/v14071515.
[27]	FENG YL, SHI XH, SHI J, et al. Immunogenicity, antibody persistence, and safety of the 60 μg hepatitis B vaccine in hemodialysis patients: A multicenter, randomized, double-blind, parallel-controlled trial[J]. Expert Rev Vaccines, 2017, 16( 10): 1045- 1052. DOI: 10.1080/14760584.2017.1367667.
[28]	YAO T, SHAO ZH, WU LN, et al. Long-term persistent immunogenicity after successful standard and triple-dosed hepatitis B vaccine in hemodialysis patients: A 3-year follow-up study in China[J]. Vaccine, 2021, 39( 18): 2537- 2544. DOI: 10.1016/j.vaccine.2021.03.074.
[29]	FENG YL, YAO T, HAN YJ, et al. Immunogenicity and safety of a high-dose and prolonged-schedule hepatitis B vaccine among chronic kidney disease patients: A randomized, parallel-controlled trial[J]. Expert Rev Vaccines, 2021, 20( 6): 743- 751. DOI: 10.1080/14760584.2021.1915777.
[30]	HAN YJ, CAO N, LU XX, et al. Duration of immunogenicity of high-dose and prolonged-schedule hepatitis B vaccine among patients with chronic kidney disease: A one year follow-up study in China[J]. Expert Rev Vaccines, 2022, 21( 11): 1675- 1682. DOI: 10.1080/14760584.2022.2112951.
[31]	FENG YL, YAO T, CHANG Y, et al. Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial[J]. Vaccine, 2021, 39( 27): 3582- 3589. DOI: 10.1016/j.vaccine.2021.05.044.
[32]	FENG YL, CHEN ZZ, XIE RX, et al. Immunogenicity and safety of 4 intramuscular standard-dose and high-dose hepatitis B vaccine in people living with HIV: A randomized, parallel-controlled trial[J]. Expert Rev Vaccines, 2022, 21( 6): 861- 868. DOI: 10.1080/14760584.2022.2056024.
[33]	SHI J, FENG YL, GAO LY, et al. Immunogenicity and safety of a high-dose hepatitis B vaccine among patients receiving methadone maintenance treatment: A randomized, double-blinded, parallel-controlled trial[J]. Vaccine, 2017, 35( 18): 2443- 2448. DOI: 10.1016/j.vaccine.2017.03.034.
[34]	YAO T, WU YT, DONG S, et al. Long-term durability of immunogenicity induced by standard and triple-dose hepatitis B vaccine in patients receiving methadone maintenance treatment[J]. Expert Rev Vaccines, 2020, 19( 9): 785- 794. DOI: 10.1080/14760584.2020.1813577.
[35]	FENG YL, YAO T, GAO YZ, et al. Immunogenicity,safety,and compliance of high- and standard-strength four dose hepatitis B vaccination regimens in patients receiving methadone maintenance therapy in China:a randomized, parallel-arm controlled trial[J]. Expert Rev Vaccines, 2021, 20( 12): 1629- 1635. DOI: 10.1080/14760584.2021.1977629.
[36]	FENG YL, SHI J, GAO LY, et al. Immunogenicity and safety of high-dose hepatitis B vaccine among drug users: a randomized, open-labeled, blank-controlled trial[J]. Hum Vaccin Immunother, 2017, 13( 6): 1- 7. DOI: 10.1080/21645515.2017.1283082.
[37]	LIAO XY, ZHUANG H. Hepatitis B vaccination without screening is safe[J]. Chin Prev Med, 2010, 11( 10): 973- 974. 廖雪雁, 庄辉. 乙型肝炎疫苗接种前不筛查是安全的[J]. 中国预防医学杂志, 2010, 11( 10): 973- 974.
[38]	ZHENG H, WANG FZ, ZHANG GM, et al. An economic analysis of adult hepatitis B vaccination in China[J]. Vaccine, 2015, 33( 48): 6831- 6839. DOI: 10.1016/j.vaccine.2015.09.011.
[39]	WAN YM, WANG FZ, ZHENG H, et al. Immunogenicity of hepatitis B vaccines in 20-49-year-old adults vaccinated using varying immunization schedules[J]. Chin J Vaccines Immun, 2020, 26( 1): 19- 24. 万咏梅, 王富珍, 郑徽, 等. 20-49岁成人乙型肝炎疫苗不同免疫程序的免疫原性比较[J]. 中国疫苗和免疫, 2020, 26( 1): 19- 24.
[40]	HAN BF, LIU W, DU J, et al. Immunogenicity and safety of hepatitis B vaccination in patients with type 2 diabetes in China: an open-label randomized controlled trial[J]. Vaccine, 2021, 39( 25): 3365- 3371. DOI: 10.1016/j. vaccine.2021.04.058.
[41]	KRUGMAN S, GILES JP, HAMMOND J. Viral hepatitis, type B(MS-2 strain) prevention with specific hepatitis B immune serum globulin[J]. JAMA, 1971, 218( 11): 1665- 1670.
[42]	ZHAO K. Research progress of hepatitis A and hepatitis B vaccines in China[J]. Chin J Vaccines Immun, 2004, 10( 4): 249- 251. 赵铠. 我国甲型肝炎与乙型肝炎疫苗研究进展[J]. 中国计划免疫, 2004, 10( 4): 249- 251.
[43]	ABRAMOWICZ M, ZUCCOTTI G, PFLOMM JM. A two-dose hepatitis B vaccine for adults(heplisav-B)[J]. JAMA, 2018, 319( 8): 822- 823. DOI: 10.1001/jama.2018.1097.
[44]	National Health and Family Planning Commission of the People’s Republic of China, National Development and Reform Commission, Ministry of Education of the People’s Republic of China, et al. Action plan for the prevention and treatment of viral hepatitis in China(2017—2020)[J]. Chin J Viral Dis, 2018, 8( 1): 1- 5. DOI: 10.16505/j.2095-0136.2018.0001. 国家卫生和计划生育委员会, 国家发展和改革委员会, 教育部, 等. 中国病毒性肝炎防治规划(2017—2020年)[J]. 中国病毒病杂志, 2018, 8( 1): 1- 5. DOI: 10.16505/j.2095-0136.2018.0001.
[45]	Chinese Prevention Medcine Association, National Immunization Program, Chinese Center for Disease Control and Prevention. Technical guide for adult hepatitis B immunization in China[J]. Chin J Epidemiol, 2011, 32( 12): 1199- 1203. DOI: 10.3760/cma.j.issn.0254-6450.2011.12.004. 中华预防医学会, 中国疾病预防控制中心免疫规划中心. 中国成人乙型肝炎免疫预防技术指南[J]. 中华流行病学杂志, 2011, 32( 12): 1199- 1203. DOI: 10.3760/cma. j.issn.0254-6450.2011.12.004.
[46]	General Office of the National Health Commission. Notice on issuing the work specifications for preventing mother-to-child transmission of HIV, syphilis and hepatitis B virus(2020 Edition)[EB/OL].( 2020-11-12)[ 2024-04-29]. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml. http: //www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml 国家卫生健康委办公厅. 关于印发预防艾滋病、梅毒和乙肝母婴传播工作规范(2020年版)的通知[EB/OL].( 2020-11-12)[ 2024-04-29]. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml. http: //www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml
[47]	CUI FQ, SHEN LP, LI L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23( 5): 765- 772. DOI: 10.3201/eid2305.161477.